Publications by authors named "C Rabbat"
Etrasimod (ADP334) is an oral, once-daily, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis and in development for the treatment of immune-mediated inflammatory diseases. Interaction between S1P and its five receptor subtypes (S1P-S1P) plays a role in several physiologic systems, including the cardiovascular and immune systems. Since differences in S1PR binding and downstream intracellular signaling could contribute to distinct profiles of drug efficacy and safety, we directly compared the S1P selectivity profile of etrasimod to three marketed S1PR modulators: fingolimod, ozanimod, and siponimod.
View Article and Find Full Text PDFBackground: Individuals receiving hemodialysis often experience concurrent symptoms during treatment and frequently report feeling unwell after dialysis. The degree to which intradialytic symptoms are related, and which specific symptoms may impair health-related quality of life (HRQoL) is uncertain.
Objectives: To explore intradialytic symptoms clusters, and the relationship between intradialytic symptom clusters with dialysis treatment recovery time and HRQoL.
Article Synopsis
- Etrasimod, an oral medication taken once daily, is being studied for its effectiveness in treating moderately to severely active ulcerative colitis (UC) through a post-hoc analysis of a phase 2 trial.
- In the trial, 156 adults were given either the drug (at doses of 1 mg or 2 mg) or a placebo over 12 weeks, with results showing that those taking the 2 mg dose had a significantly higher rate of achieving endoscopic improvement and histologic remission compared to the placebo group.
- The study also found a correlation between faecal calprotectin (FCP) and C-reactive protein (CRP) levels with treatment efficacy, suggesting that these biomarkers could be
Article Synopsis
- * The trials, ELEVATE UC 52 and ELEVATE UC 12, involved random assignments of patients to either etrasimod (2 mg) or a placebo, with ELEVATE UC 52 focusing on a longer treatment period (12-week induction followed by 40-week maintenance) and ELEVATE UC 12 assessing only the induction period at 12 weeks.
- * Both trials aimed to determine the proportion of
Rationale: Pyoderma gangrenosum is a rare neutrophilic dermatosis. Misdiagnosis of pyoderma gangrenosum as an infection is not uncommon. Pyoderma gangrenosum can be associated with Koebner phenomenon and rarely results in systemic inflammatory response syndrome and shock.
View Article and Find Full Text PDF